BCL6 activity is also impaired by another set of genetic mutations affecting the post-transcriptional regulatory mechanism of CREBBP/EP300, which impairs the acetylation-mediated BCL6 inactivation and FBXO11 mutations that occurs in 5% of DLBCL cases [88]. Here, CREBBP is linked to diffuse large B-cell lymphoma.